CBT profiles of cabozantinib approved for advanced renal cell carcinomas

Cell Biol Toxicol. 2016 Aug;32(4):259-61. doi: 10.1007/s10565-016-9349-6. Epub 2016 Jul 6.

Author

Xiangdong Wang¹

Affiliation

¹ Zhongshan Hospital Clinical Science Institute of Fudan University, Shanghai Institute of Clinical Bioinformatics, Shanghai, China. xiangdong.wang@clintransmed.org.

PMID: 27383755
DOI: 10.1007/s10565-016-9349-6

No abstract available

Publication types

Editorial
Comment